WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001083532) HELICOBACTER PYLORI ANTIGENS: FUSION OF FAY 31 AND HPA 44
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/083532    International Application No.:    PCT/SE2001/000871
Publication Date: 08.11.2001 International Filing Date: 24.04.2001
IPC:
A61K 38/00 (2006.01), A61K 39/00 (2006.01), A61K 48/00 (2006.01), C07K 14/205 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
DOIG, Peter [CA/US]; (US) (For US Only).
PAPPO, Jacques [US/US]; (US) (For US Only)
Inventors: DOIG, Peter; (US).
PAPPO, Jacques; (US)
Agent: ASTRAZENECA AB; Global Intellectual Property S-151 85 Södertälje (SE)
Priority Data:
0010370.5 29.04.2000 GB
Title (EN) HELICOBACTER PYLORI ANTIGENS: FUSION OF FAY 31 AND HPA 44
(FR) ANTIGÈNES DE HELICOBACTER PYLORI : FUSION DE FAY31 ET HPA44
Abstract: front page image
(EN)The present invention concerns a pharmaceutical product, e.g. a vaccine composition or vaccine kit, which comprises Fay31 and HOP38 polypeptides. The invention also concerns a fusion polypeptide comprising both Fay31 and HOP38 amino acid sequences, as well as a nucleic acid encoding such a fusion polypeptide. In addition, the invention concerns a pharmaceutical product comprising separate nucleotide sequences respectively encoding Fay31 and HOP38 polypeptides, Fay31 together with HOP38 provides a synergistic combination that can be used to treat and/or reduce the risk of Helicobacter pylori infection in a mammal.
(FR)La présente invention concerne un produit pharmaceutique, notamment une composition de vaccin ou un kit de vaccination, contenant des polypeptides Fay31 et HOP38. L'invention concerne également un polypeptide de fusion contenant à la fois des séquences d'acides aminées Fay31 et HOP38, et ainsi que le codage d'un acide nucléique tel un polypeptide de fusion. En plus, l'invention concerne un produit pharmaceutique comprenant des séquences de nucléotides séparées codant respectivement les polypeptides Fay31 et HOP38. Fay31 et HOP38 ensemble constituent une association synergique pouvant être utilisée pour traiter et/ou réduire le risque d'infection induite par <i>Helicobacter pylori</i> chez un mammifère.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)